Influenza Vaccines Therapeutics

Pipeline Assessment and Market Forecasts to 2018

Product Code GDA00740
Publication Date October 2011
Publisher GlobalData
Product Type Report
Pages 90
ISBN Number not applicable
Change currency
PDF £2,215.00 €2,667 $3,502 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Influenza Vaccines Therapeutics

Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global influenza vaccines vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m in 2018. The moderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza vaccines, and the approval of new influenza vaccines vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza vaccines. The upcoming influenza vaccines vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccines vaccine and Vepacel, and universal influenza vaccines vaccines such as BVX-M001, MVA-NP+M1, Flu-v and others. The influenza vaccines vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVRS-100 with Fluzone and IC31 Seasonal influenza vaccines Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian influenza vaccines (H5N1) Oral Vaccine), nasal vaccine (influenza vaccines Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic influenza vaccines Vaccine Patch).

Scope

The report provides information on the key drivers and challenges of the influenza vaccines market. Its scope includes -

  • Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) influenza vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as conjugate vaccine, combinational vaccine, polysachharide vaccines and others.
  • Analysis of the current and future competition in the seven key countries influenza vaccines market. Key market players covered are Novartis AG, GlaxoSmithKline, Sanofi, Pfizer Inc, LG Life Sciences, Sinovac Biotech and Eurocrine Vaccines.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the influenza vaccines therapeutics market.
  • Analysis of key recent licensing and partnership agreements in influenza vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global influenza vaccines market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global influenza vaccines market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What is the next big thing in the global influenza vaccines market landscape? - Identify, understand and capitalize.

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Influenza Vaccines - Introduction
    • 2.1 Disease Overview
    • 2.2 Epidemiology
    • 2.3 Etiology and Pathophysiology
      • 2.3.1 Types of Influenza Virus
      • 2.3.2 Source of Influenza Virus
      • 2.3.3 Drifting and Shifting of Influenza Virus
    • 2.4 Signs and Symptoms
    • 2.5 Diagnosis
    • 2.6 Treatment and Management Options
    • 2.7 GlobalData Pipeline Report Guidance
  • 3 Influenza Vaccines: Market Characterization
    • 3.1 Influenza Vaccines Market Size (2005-2010) - Global
    • 3.2 Influenza Vaccines Market Forecast (2011-2018) - Global
    • 3.3 Influenza Vaccines Market Size (2005-2010) - The US
    • 3.4 Influenza Vaccines Market Forecast (2011-2018) - The US
    • 3.5 Influenza Vaccines Market Size (2005-2010) - France
    • 3.6 Influenza Vaccines Market Forecast (2011-2018) - France
    • 3.7 Influenza Vaccines Market Size (2005-2010) - Germany
    • 3.8 Influenza Vaccines Market Forecast (2011-2018) - Germany
    • 3.9 Influenza Vaccines Market Size (2005-2010) - Italy
    • 3.10 Influenza Vaccines Market Forecast (2011-2018) - Italy
    • 3.11 Influenza Vaccines Market Size (2005-2010) - Spain
    • 3.12 Influenza Vaccines Market Forecast (2011-2018) - Spain
    • 3.13 Influenza Vaccines Market Size (2005-2010) - The UK
    • 3.14 Influenza Vaccines Market Forecast (2011-2018) - The UK
    • 3.15 Influenza Vaccines Market Size (2005-2010) - Japan
    • 3.16 Influenza Vaccines Market Forecast (2011-2018) - Japan
    • 3.17 Drivers and Barriers for the Influenza Vaccines Market
      • 3.17.1 Drivers for the Influenza Vaccines Market
      • 3.17.2 Barriers for the Influenza Vaccines Market
    • 3.18 Opportunity and Unmet Need Analysis
    • 3.19 Key Takeaway
  • 4 Influenza Vaccines: Competitive Assessment
    • 4.1 Overview
    • 4.2 5.1.1 Strategic Competitor Assessment
    • 4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market
      • 4.3.1 Fluarix
      • 4.3.2 FluLaval
      • 4.3.3 Flumist
      • 4.3.4 Fluvirin
      • 4.3.5 Fluzone
    • 4.4 Key Takeaway
  • 5 Influenza Vaccines - Pipeline Assessment
    • 5.1 Overview
    • 5.2 Strategic Pipeline Assessment
      • 5.2.1 Influenza Vaccines Pipeline - Pipeline by Phases of Development
      • 5.2.2 Influenza Vaccines - Regulatory Filed Products
      • 5.2.3 Influenza Vaccines - Phase III Pipeline
      • 5.2.4 Influenza Vaccines - Phase II Pipeline
      • 5.2.5 Influenza Vaccines - Phase I Pipeline
      • 5.2.6 Influenza Vaccines - Pre-Clinical Pipeline
      • 5.2.7 Influenza Vaccines - Discovery Pipeline
      • 5.2.8 Technology Trends Analytical Framework
    • 5.3 Influenza Vaccines - Clinical Pipeline by Types of Vaccine
    • 5.4 Influenza Vaccines - Promising Drugs Under Clinical Development
    • 5.5 Molecule Profile for Promising Drugs Under Clinical Development
      • 5.5.1 FluBlok
      • 5.5.2 Flu Vaccine
      • 5.5.3 MEDI 3250
      • 5.5.4 A-04-01D Vaccine
      • 5.5.5 H5N1 Pandemic Influenza Vaccine
      • 5.5.6 Vepacel
    • 5.6 Key Takeaway
  • 6 Influenza Vaccines: Clinical Trials Mapping
    • 6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
    • 6.2 Clinical Trials by Phase
    • 6.3 Clinical Trials by Trial Status
    • 6.4 Prominent Sponsors
    • 6.5 Top Companies Participating in Influenza Vaccines Clinical Trials
  • 7 Influenza Vaccines: Strategic Assessment
    • 7.1 Key Events Impacting the Future Market
    • 7.2 Influenza Vaccines: Implications for Future Market Competition
  • 8 Influenza Vaccines: Future Players
    • 8.1 Introduction
    • 8.2 Company Profiles
      • 8.2.1 AstraZeneca PLC
      • 8.2.2 GlaxoSmithKline plc
      • 8.2.3 Novartis AG
      • 8.2.4 Baxter International Inc.
  • 9 Influenza Vaccines: Licensing and Partnership Deals
  • 10 Influenza Vaccines: Appendix
    • 10.1 Market Definitions
    • 10.2 Abbreviations
    • 10.3 Methodology
      • 10.3.1 Coverage
      • 10.3.2 Secondary Research
      • 10.3.3 Forecasting
      • 10.3.4 Primary Research
      • 10.3.5 Expert Panel Validation
    • 10.4 Contact Us
    • 10.5 Disclaimer
    • 10.6 Bibliography
    • 1.1 List of Tables
      • Table 1: Influenza Vaccines Market, Global, Revenue ($m), 2005-2010
      • Table 2: Influenza Vaccines Market, Global, Forecast ($m), 2011-2018
      • Table 3: Influenza Vaccines Market, The US, Revenue ($m), 2005-2010
      • Table 4: Influenza Vaccines Market, The US, Forecasts ($m), 2011-2018
      • Table 5: Influenza Vaccines Market, France, Revenue ($m), 2005-2010
      • Table 6: Influenza Vaccines Market, France, Forecasts ($m), 2011-2018
      • Table 7: Influenza Vaccines Market, Germany, Revenue ($m), 2005-2010
      • Table 8: Influenza Vaccines Market, Germany, Forecasts ($m), 2011-2018
      • Table 9: Influenza Vaccines Market, Italy, Revenue ($m), 2005-2010
      • Table 10: Influenza Vaccines Market, Italy, Forecasts ($m), 2011-2018
      • Table 11: Influenza Vaccines Market, Spain, Revenue ($m), 2005-2010
      • Table 12: Influenza Vaccines Market, Spain, Forecasts ($m), 2011-2018
      • Table 13: Influenza Vaccines Market, The UK, Revenue ($m), 2005-2010
      • Table 14: Influenza Vaccines Market, The UK, Forecasts ($m), 2011-2018
      • Table 15: Influenza Vaccines Market, Japan, Revenue ($m), 2005-2010
      • Table 16: Influenza Vaccines Market, Japan, Forecasts ($m), 2011-2018
      • Table 17: Influenza Vaccines - Regulatory Filed Products, 2011
      • Table 18: Influenza Vaccines - Phase III Pipeline, 2011
      • Table 19: Influenza Vaccines - Phase II Pipeline, 2011
      • Table 20: Influenza Vaccines - Phase I Pipeline, 2011
      • Table 21: Influenza Vaccines - Pre-Clinical Pipeline, 2011
      • Table 22: Influenza Vaccines - Discovery Pipeline, 2011
      • Table 23: Influenza Vaccines - Most Promising Drugs Under Clinical Development, 2011
      • Table 24: Influenza Vaccines - Clinical Trials by Country, 2011
      • Table 25: Influenza Vaccines - Clinical Trials by Phase, 2011
      • Table 26: Influenza Vaccines - Clinical Trials by Status, 2011
      • Table 27: Influenza Vaccines - Overall Sponsors, 2011
      • Table 28: Influenza Vaccines - Prominent Sponsors, 2011
      • Table 29: Influenza Vaccines - Top Companies Participating in Clinical Trials, 2011
      • Table 30: Astrazeneca - Influenza Pipeline Products, 2011
      • Table 31: GlaxoSmithKline - Influenza Pipeline Products, 2011
      • Table 32: Novartis AG - Influenza Pipeline Products, 2011
      • Table 33: Baxter International - Influenza Pipeline Products, 2011
      • Table 34: Influenza Vaccines: Licensing and Partnership Deals, 2011
    • 1.2 List of Figures
      • Figure 1: Comparison of Seasonal and Pandemic Influenza
      • Figure 2: Comparison of Influenza A, B and C
      • Figure 3: Comparison of Influenza and the Common Cold
      • Figure 4: Influenza Virus Testing Methods
      • Figure 5: Clinical Algorithm for Consideration in the Assessment of Persons with Mild or Uncomplicated Influenza Illness
      • Figure 6: Influenza Vaccines Market, Global, Revenue ($m), 2005-2010
      • Figure 7: Influenza Vaccines Market, Global, Forecast ($m), 2011-2018
      • Figure 8: Influenza Vaccines Market, The US, Revenue ($m), 2005-2010
      • Figure 9: Influenza Vaccines Market, The US, Forecast ($m), 2011-2018
      • Figure 10: Influenza Vaccines Market, France, Revenue ($m), 2005-2010
      • Figure 11: Influenza Vaccines Market, France, Forecast ($m), 2011-2018
      • Figure 12: Influenza Vaccines Market, Germany, Revenue ($m), 2005-2010
      • Figure 13: Influenza Vaccines Market, Germany, Forecast ($m), 2011-2018
      • Figure 14: Influenza Vaccines Market, Italy, Revenue ($m), 2005-2010
      • Figure 15: Influenza Vaccines Market, Italy, Forecast ($m), 2011-2018
      • Figure 16: Influenza Vaccines Market, Spain, Revenue ($m), 2005-2010
      • Figure 17: Influenza Vaccines Market, Spain, Forecast ($m), 2011-2018
      • Figure 18: Influenza Vaccines Market, The UK, Revenue ($m), 2005-2010
      • Figure 19: Influenza Vaccines Market, The UK, Forecast ($m), 2011-2018
      • Figure 20: Influenza Vaccines Market, Japan, Revenue ($m), 2005-2010
      • Figure 21: Influenza Vaccines Market, Japan, Forecast ($m), 2011-2018
      • Figure 22: Opportunity and Unmet Need in the Influenza Vaccines Market
      • Figure 23: Influenza Vaccines - Strategic Competitor Assessment, 2010
      • Figure 24: Influenza Vaccines - Pipeline by Phase of Development, 2011
      • Figure 25: Influenza Vaccines - Technology Trends Analytics Framework, 2011
      • Figure 26: Influenza Vaccines - Technology Trends Analytics Framework - Description, 2011
      • Figure 27: Influenza Vaccines - Pipeline by Types of Vaccines, 2011
      • Figure 28: Influenza Vaccines - Clinical Trials by Country, 2011
      • Figure 29: Influenza Vaccines - Clinical Trials by Phase, 2011
      • Figure 30: Influenza Vaccines - Clinical Trials by Status, 2011
      • Figure 31: Influenza Vaccines - Overall Sponsors, 2011
      • Figure 32: Influenza Vaccines - Prominent Sponsors, 2011
      • Figure 33: Influenza Vaccines - Top Companies Participating in Clinical Trials, 2011
      • Figure 34: Influenza Vaccines Market, Drivers and Barriers, 2011
      • Figure 35: Implications for Future Market Competition in the Influenza Vaccines Market, 2011
      • Figure 36: Influenza Vaccines Market - Pipeline by Company, 2011
      • Figure 37: GlobalData Market Forecasting Model